<DOC>
	<DOCNO>NCT01149109</DOCNO>
	<brief_summary>The prognosis patient newly diagnose glioblastoma dismal despite recent therapeutic improvement Using standard therapy temozolomide ( TMZ ) radiotherapy ( 60 Gy ) , median overall survival time ( mOS ) 14.6 month ( Stupp et al. , 2005 ) . Since previous non-randomized bicentric phase II trial , primary combination chemotherapy lomustine ( CCNU ) TMZ highly effective ( mOS 23 month ; UKT-03 trial ; Herrlinger et al. , 2006 ; Glas et al. , 2009 ) propose trial investigate efficacy CCNU/TMZ randomize multicenter phase III set standard therapy . In case project phase III trial confirms phase II data , CCNU/TMZ combination would significantly better TMZ monotherapy would thus new standard treatment newly diagnose GBM patient methylated MGMT promotor . Thus , trial potential profoundly change standard therapy aggressive brain tumor . Since previous trial patient methylated MGMT ( mMGMT ) promoter benefit CCNU/TMZ ( mOS mMGMT group 34 month , non-mMGMT group 12.5 month ; Glas et al. , 2009 ) patient non-methylated MGMT benefit , trial restrict mMGMT patients.The CeTeG trial randomize 1:1 fashion newly diagnose GBM patient ( 18-70 year ) either standard TMZ therapy ( concomitant 6 course à 4 week adjuvant TMZ therapy ) experimental CCNU/TMZ therapy ( 6 course à 6 week ) . Both arm include standard radiotherapy ( RT ) tumor site ( 30 x 2 Gy ) . Assuming CCNU/TMZ therapy increase median overall survival ( mOS ) 48.9 % ( standard TMZ ) 70 % ( CCNU/TMZ ; 75 % previous phase II trial , Glas et al. , 2009 ) , 2 x 68 patient accrue . Patients accrue 24 month patient follow least 24 month add total minimal duration time first patient end follow-up time 48 month . The primary endpoint overall survival ; secondary endpoint include progression-free survival , response rate , acute late toxicity , quality life .</brief_summary>
	<brief_title>Efficacy Safety Study Lomustine/Temozolomide Combination Therapy vs. Standard Therapy Glioblastoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>write informed consent patient cognitive state allows understand rationale necessity study therapy procedure . newly diagnose histologically proven GBM gliosarcoma WHO Grad IV methylated MGMT promoter tumor estimate life expectancy least 12 week Karnofsky Performance Score ( KPS ) ≥ 70 % patient compliance geographic proximity allow adequate follow male female patient reproductive potential must use approved contraceptive method premenopausal female patient childbearing potential : negative serum pregnancy test must obtain prior treatment start Adequate organ function describe : Adequate bone marrow reserve : white blood cell ( WBC ) count &gt; 3000/µl , granulocyte count &gt; 1500/µl , platelet &gt; 100000/µl , haemoglobin ≥ 10 g/dl Adequate liver function bilirubin &lt; 1.5 time upper limit normal range ( ULN ) , ALT AST &lt; 3 time ULN creatinine &lt; 1.5 time ULN Adequate blood clotting : PT PTT within normal limit Negative HIV test prior malignancy prior chemotherapy prior radiotherapy brain concurrent administration antitumor therapy allergy intolerability temozolomide , CCNU , dacarbazine nitrosourea derivative unable undergo MRI past medical history disease poor prognosis know HIV infection , active Hepatitis B C infection active infection female patient pregnant breastfeed patient reproductive potential accept use contraception treatment another clinical trial psychological , cognitive , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule visit ( discretion investigator )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>MGMT promotor status</keyword>
	<keyword>overall survival</keyword>
</DOC>